XCEEDANCE
3.3.2020 09:02:14 CET | Business Wire | Press release
Xceedance , a global provider of insurance consulting, managed services, technology, data sciences, and blockchain solutions, today launched its life insurance and reinsurance practice and announced the establishment of an office in Liechtenstein to serve life re/insurance markets.
The practice focuses on partnering with existing and start-up life re/insurance organisations and insurtech providers, offering services such as interim management, strategic consulting, product development, actuarial services, sales strategy consulting, Solvency II Pillar 1-2 support, and reinsurance optimisation. In addition, Xceedance can help carriers with legacy transformation to better manage new and existing business, and to transact run-off portfolios.
Markus Brugger and Mark Lucas will jointly direct the newest international office of Xceedance, as leaders of the life insurance and reinsurance sectors respectively.
“Liechtenstein is a significant financial services hub, including for worldwide life re/insurers, and our rapidly growing company is especially skilled in supporting the full range of insurance operations, as we help our global clients gain new business, grow revenues and minimise expenses,” said Arun Balakrishnan, CEO, Xceedance. “We are excited to locate an office in Liechtenstein and expand opportunities for direct interaction with diverse life re/insurance organisations, both in the EMEA region and worldwide.”
“Liechtenstein is a well-established global insurance marketplace, and Xceedance can help and support life re/insurers worldwide to strengthen their operations and enter new markets,” said Markus Brugger.
“We are excited to join a dynamic company such as Xceedance and look forward to building the company’s life re/insurance consulting and technology services to assist the industry in addressing pressing challenges and diverse market opportunities,” said Mark Lucas.
Mr. Brugger has 30 years of life re/insurance experience and was president of the Liechtenstein Insurance Association from 2012 to 2014. He has held senior roles with Winterthur Re, Cologne Re, and PartnerRe, and was CEO for 17 years at PrismaLife and Liechtenstein Life. Mr. Brugger joins Xceedance from Grant Thornton Liechtenstein/Switzerland, where he led the insurance advisory practice.
Mr. Lucas has 35 years of industry experience at Guy Carpenter in Denmark, U.S. Re in Switzerland, and most recently at JLT Re in Switzerland, where he was general manager. Mr. Lucas has developed several new reinsurance products over his career and brings a wealth of life reinsurance knowledge to Xceedance.
About Xceedance
Xceedance (www.xceedance.com ) is a global provider of strategic consulting, actuarial, and managed services, technology, and data sciences to property/casualty and life insurance organisations. Domiciled in Bermuda, with offices in the United States, United Kingdom, Germany, Liechtenstein, Poland, India, and Australia, Xceedance helps re/insurers launch new products, drive operations, implement intelligent technology and blockchain solutions, deploy advanced analytic capabilities, and achieve business process optimisation. The experienced insurance professionals at Xceedance enable re/insurers, brokers, TPAs, agents, and program administrators worldwide to enhance policyholder service, enter new markets, boost workflow productivity, and improve profitability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes12.5.2026 08:00:00 CEST | Press release
Merz Therapeutics to present 11 abstracts at ISPRM World Congress 2026, highlighting its commitment to improving outcomes for people living with movement disorders Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN®) Updated meta-analyses examining secondary treatment failure and neutralizing antibodies suggest a potential for sustained long-term treatment response with incobotulinumtoxinA (XEOMIN®) Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17th to May 21st in Vancouver, Canada, the presentations will feature key data on optimal dosin
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook12.5.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 +3.1% Adjusted EBITDA (4) 404 280 +57.0% 425 +5.0% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralise currency variations 3) ‘Like-for-like basis’ is as if Intelsat fully consolidated from 1 January 2024 4) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +106.0% yoy(1) supported by growth in Mobility (+207.8% yoy(1); including positive impact from a contract restructuring in Aviation) and Gov
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI12.5.2026 03:00:00 CEST | Press release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/ GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure. Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment. Deployable: modular clusters engineered for rapid implementation across diverse environments.
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom